

PROVINCIAL FUNDING SUMMARY

Ramucirumab (Cyramza) for Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma

pERC Recommendation: Recommends

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: November 13, 2015

This information is current as of September 13, 2017.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	May 1, 2017	In combination with paclitaxel for metastatic or locally advanced (unresectable) gastric or gastro-esophageal junction adenocarcinoma. • Disease progression after first-line chemotherapy • ECOG performance status 0-1 • Adequate hematologic, liver, and cardiac function • BC Cancer Agency Compassionate Access Program (CAP) approval
AB	Funded	Apr 3, 2017	Ramucirumab in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with ECOG performance status of 0 or 1 and with disease progression following first line chemotherapy.
SK	Funded	Dec 21, 2016	In combination with Paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma with an ECOG performance status of 0 or 1, and with disease progression following first-line chemotherapy.
MB	Funded	Dec 12, 2016	Ramucirumab in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and with disease progression following first-line chemotherapy.
ON	Funded	Feb 28, 2017	Ramucirumab in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and with disease progression following first-line chemotherapy.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NS	Funded	May 30, 2017	In combination with paclitaxel for patients with advanced or metastatic gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma with an ECOG performance status 0-1 and with disease progression following first line chemotherapy.
NB	Funded	Aug 24, 2017	In combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma with an ECOG performance status of 0 or 1, and with disease progression following first-line chemotherapy.
NL	Funded	Aug 3, 2017	In combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with an Eastern Cooperative Oncology Group performance status of 0 or 1 and with disease progression following first line chemotherapy.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.